Advancing therapeutics targeting cytokines with functional cell-based assays

6 March 2024


Watch this webinar to discover functional cell-based assays for characterizing novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.


Register to join this webinar discussion for free

Therapeutics targeting inflammatory cytokines that produce Th17- or Th2- (helper T cells) mediated immune responses have demonstrated significant clinical impact in several diseases, including psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, asthma, & atopic dermatitis. Several important agents inhibiting Th17 immune responses, including approved drugs such as risankizumab & guselkumab, target IL-23, while others, like secukinumab, target IL-17. In the Th2 pathway, the anti-IL-4/IL-13 antibody dupilumab has been successfully employed for the treatment of asthma & atopic dermatitis, with many other indications still under evaluation. Eurofins DiscoverX has established a portfolio of cell-based assays to aid in the characterization of therapeutics targeting these important cytokines utilizing the PathHunter® enzyme fragment complementation technology.

In this webinar, we share case studies on the use of cell-based assays that monitor receptor dimerization or pathway activation (e.g. transcriptional reporters) targeting IL-23, IL-12, IL-17, & IL-4/IL-13 for a variety of applications, including rank ordering of antibodies, evaluating antibody specificity, as well as detection of anti-drug neutralizing antibodies.

Data demonstrating the suitability of these assays for determining relative potency to support lot-release applications during manufacture & drug product release will also be shared. Finally, new assays targeting emerging therapeutic targets for inflammation, such as IL-7 & TSLP, will be highlighted.

Key learning points

  • Review key cytokines involved in inflammatory diseases & examples of clinically successful marketed therapeutics targeting these cytokines
  • Examine case studies highlighting the application of various cell-based assay formats to assess the mechanism of action of antibodies targeting existing & emerging cytokine targets in inflammatory disease
  • Understand optimal assay formats for assessing antibody specificity vs successful detection of neutralizing antibodies in cell-based assays
  • Learn about the breadth of PathHunter cytokine assays available for characterization of novel therapeutics & biosimilars targeting cytokines in inflammation & oncology.

Register now to secure your seat.


CytokinesJennifer Lin-Jones, Ph.D, Associate Director of Assay Development R&D Department, Eurofins DiscoverX

Dr. Jennifer Lin-Jones is Associate Director of Assay Development at Eurofins DiscoverX where she has been a major contributor in novel cell-based assay and tool development to support the expansive Eurofins DiscoverX assay portfolio as well as assays for client-focused projects.  Jennifer received her B.S. from MIT, Ph.D. in Zoology from the University of Washington and was a post-doc at University of California, Berkeley.




Is the webinar free? 

Yes – there is no charge to watch the webinar, either live or on-demand. 

When will the webinar take place? 

6th March 2024 at 4.00pm GMT/8am PST. 

Can I watch it later? 

The webinar will become available to watch on-demand shortly after the live webinar takes place. 

What are the benefits of attending live? 

You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session. 

How long will the webinar be? 

This webinar will last up to an hour. 

What do I need to watch this webinar? 

All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.